|
1
|
Elserag HB and Rudolph KL: Hepatocellular
carcinoma: Epidemiology and molecular carcinogenesis.
Gastroenterology. 132:2557–2576. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wang JS, Huang T, Su J, Liang F, Wei Z,
Liang Y, Luo H, Kuang SY, Qian GS, Sun G, et al: Hepatocellular
carcinoma and aflatoxin exposure in Zhuqing Village, Fusui County,
People's Republic of China. Cancer Epidemiol Biomarkers Prev.
10:143–146. 2001.PubMed/NCBI
|
|
3
|
Alloatti A, Testero SA and Uttaro AD:
Chemical evaluation of fatty acid desaturases as drug targets in
Trypanosoma cruzi. Int J Parasitol. 39:985–993. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Burrel M, Reig M, Forner A, Barrufet M, de
Lope CR, Tremosini S, Ayuso C, Llovet JM, Real MI and Bruix J:
Survival of patients with hepatocellular carcinoma treated by
transarterial chemoembolisation (TACE) using drug eluting beads.
Implications for clinical practice and trial design. J Hepatol.
56:1330–1335. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Boas FE, Kamaya A, Do B, Desser TS,
Beaulieu CF, Vasanawala SS, Hwang GL and Sze DY: Classification of
hypervascular liver lesions based on hepatic artery and portal vein
blood supply coefficients calculated from triphasic CT scans. J
Digit Imaging. 28:213–223. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brade AM, Ng S, Brierley J, Kim J,
Dinniwell R, Ringash J, Wong RR, Cho C, Knox J and Dawson LA: Phase
1 trial of sorafenib and stereotactic body radiation therapy for
hepatocellular carcinoma. Int J Radiat Oncol Biol Phys. 94:580–587.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Brock TJ, Browse J and Watts JL: Genetic
regulation of unsaturated fatty acid composition in C. elegans.
PLoS Genet. 2:e1082006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jia ZZ, Jiang GM and Feng YL: Serum
HIF-1alpha and VEGF levels pre- and post-TACE in patients with
primary liver cancer. Chin Med Sci J. 26:158–162. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chen J, Zhang WJ, Guo Z, Wang HB, Wang DD,
Zhou JJ and Chen QW: pH-responsive iron manganese silicate
nanoparticles as T1-T2* dual-modal imaging probes for tumor
diagnosis. ACS Appl Mater Interfaces. 7:5373–5383. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Das S, Ladell DS, Podgrabinska S,
Ponomarev V, Nagi C, Fallon JT and Skobe M: Vascular endothelial
growth factor-C induces lymphangitic carcinomatosis, an extremely
aggressive form of lung metastases. Cancer Res. 70:1814–1824. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Di Costanzo GG, Tortora R, Morisco F,
Addario L, Guarino M, Cordone G, Falco L and Caporaso N: Impact of
diabetes on outcomes of sorafenib therapy for hepatocellular
carcinoma. Target Oncol. 12:61–67. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Enoch HG, Catalá A and Strittmatter P:
Mechanism of rat liver microsomal stearyl-CoA desaturase. Studies
of the substrate specificity, enzyme-substrate interactions, and
the function of lipid. J Biol Che. 251:5095–5103. 1976.
|
|
13
|
Funami Y, Okuyama K, Koide Y, Kouzu T,
Kinoshita H, Shimada Y and Isono K: Anatomical analysis of small
bronchial arteries in front of the trachea by 3D-CT and digital
subtraction angiography: Implications for esophageal cancer
surgery. Nihon Geka Gakkai Zasshi. 96:207–212. 1995.(In Japanese).
PubMed/NCBI
|
|
14
|
Kim BK, Kim SU, Park JY, Kim DY, Ahn SH,
Park MS, Kim EH, Seong J, Lee DY and Han KH: Applicability of BCLC
stage for prognostic stratification in comparison with other
staging systems: single centre experience from long-term clinical
outcomes of 1717 treatment-naïve patients with hepatocellular
carcinoma. Liver Int. 32:1120–1127. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Han K and Kim JH: Transarterial
chemoembolization in hepatocellular carcinoma treatment: Barcelona
clinic liver cancer staging system. World J Gastroenterol.
21:10327–10335. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Iavarone M, Cabibbo G, Piscaglia F,
Zavaglia C, Grieco A, Villa E, Cammà C and Colombo M: SOFIA
(SOraFenib Italian Assessment) study group: Field-practice study of
sorafenib therapy for hepatocellular carcinoma: A prospective
multicenter study in Italy. Hepatology. 54:2055–2063. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Park JW, Koh YH, Kim HB, Kim HY, An S,
Choi JI, Woo SM and Nam BH: Phase II study of concurrent
transarterial chemoembolization and sorafenib in patients with
unresectable hepatocellular carcinoma. J Hepatol. 56:1336–1342.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Igal RA: Roles of stearoylCoA desaturase-1
in the regulation of cancer cell growth, survival and
tumorigenesis. Cancers (Basel). 3:2462–2477. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Llovet JM, Brã C and Bruix J: Prognosis of
hepatocellular carcinoma: The BCLC staging classification. Semin
Liver Dis. 19:329–338. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wang ZL: Research on the security and
clinical curative effect of TACE combined with sorafenib in the
treatment of hepatocellular carcinoma in the middle and late
period. China Foreign Med Treat. 1:126–127. 2016.
|
|
21
|
Chung YH, Han G, Yoon JH, Yang J, Wang J,
Shao GL, Kim BI, Lee TY and Chao Y: Interim analysis of START:
Study in Asia of the combination of TACE (transcatheter arterial
chemoembolization) with sorafenib in patients with hepatocellular
carcinoma trial. Int J Cancer. 132:2448–2458. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li X, Feng GS, Zheng CS, Zhuo CK and Liu
X: Expression of plasma vascular endothelial growth factor in
patients with hepatocellular carcinoma and effect of transcatheter
arterial chemoembolization therapy on plasma vascular endothelial
growth factor level. World J Gastroenterol. 10:2878–2882. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yamaguchi R, Yano H, Iemura A, Ogasawara
S, Haramaki M and Kojiro M: Expression of vascular endothelial
growth factor in human hepatocellular carcinoma. Hepatology.
28:68–77. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Poon RT, Lau CP, Ho JW, Yu WC, Fan ST and
Wong J: Tissue factor expression correlates with tumor angiogenesis
and invasiveness in human hepatocellular carcinoma. Clin Cancer
Res. 9:5339–5345. 2003.PubMed/NCBI
|
|
25
|
Maio MD, Daniele B and Perrone F: Targeted
therapies: Role of sorafenib in HCC patients with compromised liver
function. Nat Rev Clin Oncol. 6:505–506. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wilhelm SM, Adnane L, Newell P, Villanueva
A, Llovet JM and Lynch M: Preclinical overview of sorafenib, a
multikinase inhibitor that targets both Raf and VEGF and PDGF
receptor tyrosine kinase signaling. Mol Cancer Ther. 7:3129–3140.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang L, Hu P, Chen X and Bie P:
Transarterial chemoembolization (TACE) plus sorafenib versus TACE
for intermediate or advanced stage hepatocellular carcinoma: A
meta-analysis. PLoS One. 9:e1003052014. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ooka Y, Kanai F, Okabe S, Ueda T,
Shimofusa R, Ogasawara S, Chiba T, Sato Y, Yoshikawa M and Yokosuka
O: Gadoxetic acid-enhanced MRI compared with CT during angiography
in the diagnosis of hepatocellular carcinoma. Magn Reson Imaging.
31:748–754. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Rossi S, Garbagnati F, Lencioni R,
Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi
C, Mazzaferro V, et al: Percutaneous radio-frequency thermal
ablation of nonresectable hepatocellular carcinoma after occlusion
of tumor blood supply. Radiology. 217:119–126. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Numata K, Tanaka K, Kiba T, Saito S,
Isozaki T, Hara K, Morimoto M, Sekihara H, Yonezawa H and Kubota T:
Using contrast-enhanced sonography to assess the effectiveness of
transcatheter arterial embolization for hepatocellular carcinoma.
AJR Am J Roentgenol. 176:1199–1205. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Koito K, Namieno T, Ichimura T, Hirokawa
N, Syonai T, Hareyama M, Katsuramaki T, Hirata K and Nishi M: Power
Doppler sonography: Evaluation of hepatocellular carcinoma after
treatment with transarterial embolization or percutaneous ethanol
injection therapy. AJR Am J Roentgenol. 174:337–341. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Breedis C and Young G: The blood supply of
neoplasms in the liver. Am J Pathol. 30:969–977. 1954.PubMed/NCBI
|
|
33
|
Yamasaki T, Kurokawa F, Shirahashi H,
Kusano N, Hironaka K and Okita K: Percutaneous radiofrequency
ablation therapy for patients with hepatocellular carcinoma during
occlusion of hepatic blood flow. Comparison with standard
percutaneous radiofrequency ablation therapy. Cancer. 95:2353–2360.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Burrel M, Llovet JM, Ayuso C, Iglesias C,
Sala M, Miquel R, Caralt T, Ayuso JR, Solé M, Sanchez M, et al: MRI
angiography is superior to helical CT for detection of HCC prior to
liver transplantation: An explant correlation. Hepatology.
38:1034–1042. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kudo M: Imaging blood flow characteristics
of hepatocellular carcinoma. Oncology. 62 Suppl 1:S48–S56. 2002.
View Article : Google Scholar
|
|
36
|
Woo HY, Heo J, Yoon KT, Kim GH, Kang DH,
Song GA and Cho M: Clinical course of sorafenib treatment in
patients with hepatocellular carcinoma. Scand J Gastroenterol.
47:809–819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Tsurusaki M and Murakami T: Surgical and
locoregional therapy of HCC: TACE. Liver Cancer. 4:165–175. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wan X, Zhai X, Yan Z, Yang P, Li J, Wu D,
Wang K, Xia Y and Shen F: Retrospective analysis of transarterial
chemoembolization and sorafenib in Chinese patients with
unresectable and recurrent hepatocellular carcinoma. Oncotarget.
7:83806–83816. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Pressiani T, Boni C, Rimassa L, Labianca
R, Fagiuoli S, Salvagni S, Ferrari D, Cortesi E, Porta C,
Mucciarini C, et al: Sorafenib in patients with Child-Pugh class A
and B advanced hepatocellular carcinoma: A prospective feasibility
analysis. Ann Oncol. 24:406–411. 2013. View Article : Google Scholar : PubMed/NCBI
|
